Physician
Cisse, Babacar
Cisse, Babacar was paid $31K by Medicaid between Feb 2022 and Nov 2024, across 11 billing codes. Its largest line is 99212, Office or other outpatient visit for the evaluation and management of an established patient, straightforward — 44% of everything it billed.
33Billing provider infoCISSE, BABACAR
NEW YORK, NY 10065
NEW YORK, NY 10065
33aNPI1619292489assigned 04/05/2010
33bProvider typeNeurological Surgery Physician
28Total paid$31K
24GClaims3,223
24DCodes billed11
24AFirst – last monthFeb 2022 – Nov 2024
Compared with peers
Next to other Neurological Surgery Physician providers in New York
Rank by total paid#20 of 80
Median peer was paid$3K
This provider vs. median9.7×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2022 | 975 | $8K | |
| 2023 | 800 | $7K | |
| 2024incomplete | 1,448 | $16K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 44% | 1,220 | 1,096 | $14K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 18% | 229 | 221 | $6K |
| 87636 | Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B | 16% | 186 | 176 | $5K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 13% | 274 | 270 | $4K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 4.2% | 75 | 75 | $1K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2.0% | 261 | 241 | $609.96 |
| G2211 | Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's single, serious condition or a complex condition. (add-on code, list separately in addition to office/outpatient evaluation and management visit, new or established) | 1.7% | 458 | 365 | $535.20 |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 75 | 75 | $254.38 |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 64 | 57 | $111.33 |
| 99000 | 0% | 366 | 358 | $0.00 | |
| 36415 | Collection of venous blood by venipuncture | 0% | 15 | 14 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.